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Abstract
Background: To determine clinical outcomes and cure rates for M.genitalium genital infection in men and women following
azithromycin 1 g.
Methodology: Patients attending Melbourne Sexual Health Centre between March 2005 and November 2007 with
urethritis/epididymitis, cervicitis/pelvic inflammatory disease and sexual contacts of M.genitalium were tested for
M.genitalium by polymerase chain reaction (PCR). M.genitalium-infection was treated with 1 g of azithromycin and a test-
of-cure (toc) was performed one month post-azithromycin. Response to azithromycin, and response to moxifloxacin
(400 mg daily for 10 days) in individuals with persistent infection post-azithromycin, was determined.
Principal Findings: Of 1538 males and 313 females tested, 161 males (11%) and 30 females (10%) were infected with
M.genitalium. A toc was available on 131 (69%) infected individuals (median=36 days [range 12-373]). Of 120 individuals
prescribed azithromycin only pre-toc, M.genitalium was eradicated in 101 (84%, 95% confidence intervals [CI]: 77–90%) and
persisted in 19 (16%, 95% CI: 10–23%). Eleven individuals with persistent infection (9%, 95% CI: 5–15%) had no risk of
reinfection from untreated-partners, while eight (7%, 95% CI: 3–12%) may have been at risk of reinfection from doxycycline-
treated or untreated-partners. Moxifloxacin was effective in eradicating persistent infection in all cases not responding to
azithromycin. Patients with persistent-M.genitalium were more likely to experience persistent symptoms (91%), compared to
patients in whom M.genitalium was eradicated (17%), p,0.0001.
Conclusion: Use of azithromycin 1 g in M.genitalium-infected patients was associated with unacceptable rates of persistent
infection, which was eradicated with moxifloxacin. These findings highlight the importance of follow-up in M.genitalium-
infected patients prescribed azithromycin, and the need to monitor for the development of resistance. Research to
determine optimal first and second-line therapeutic agents for M.genitalium is needed.
Citation: Bradshaw CS, Chen MY, Fairley CK (2008) Persistence of Mycoplasma genitalium Following Azithromycin Therapy. PLoS ONE 3(11): e3618. doi:10.1371/
journal.pone.0003618
Editor: Patricia Kissinger, Tulane University, United States of America
Received July 15, 2008; Accepted October 14, 2008; Published November 3, 2008
Copyright:  2008 Bradshaw et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CSB holds a National Medical and Research Council Research Fellowship, Grant ID 465164.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cbradshaw@mshc.org.au
Introduction
M.genitalium is a cause of urethritis in men and cervicitis in
women [1], has been isolated from women with endometritis and
salpingitis, and has been implicated in tubal factor infertility
[2,3,4,5,6]. In vitro studies have shown that M.genitalium is most
susceptible to macrolides, particularly to azithromycin, but that
it has reduced susceptibility to tetracyclines and some fluoro-
quinolones [7,8]. Clinical studies using doxycycline and levo-
floxacin also show significant failure rates following these
therapies [8,9,10,11,12,13]. Two trials have compared azithro-
mycin to doxycycline for the treatment of M. genitalium. In both
of these, 1 g of azithromycin was shown to be more effective (84–
85%) than 7–9 days of doxycyline (35–36%) [12,13]. In 53
individuals failing doxycycline, an extended course of azithro-
mycin (500 mg followed by 250 mg daily for 4 days) eradicated
M. genitalium in 47 men (96%) and 6 (100%) women. However,
extended azithromycin therapy was not statistically superior to
azithromycin 1 g [12].
Current international guidelines recommend azithromycin 1 g
as first-line therapy for uncomplicated M.genitalium infection [14];
however second-line agents have not been extensively evaluated.
Importantly, azithromycin 1 g is also first-line therapy for non-
gonococcal urethritis (NGU) in most countries, resulting in a high
proportion of patients with symptomatic M.genitalium-positive
NGU receiving azithromycin presumptively. In 2006 we reported
high rates of treatment failure following azithromycin 1 g in men
with M.genitalium-associated urethritis (28%, 95% confidence
interval (CI),15–45%) [15]. Reduced susceptibility to azithromycin
of these isolates demonstrated that azithromycin-resistance rather
than re-infection was responsible for treatment failure, and that
test positivity was not due to detection of persistent non-viable
DNA. M. genitalium was successfully eradicated in all men
experiencing azithromycin failure using 400 mg daily of moxi-
floxacin for 10 days.
In this study, we aimed to determine likely levels of
azithromycin treatment failure using a large number of M.
genitalium-infected individuals. Furthermore, we sought to deter-
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M.genitalium, including those who failed to respond to azithromy-
cin, and to examine treatment response to moxifloxacin in those in
whom azithromycin did not eradicate infection. Establishing levels
of azithromycin resistance and effective second-line agents for the
treatment of M.genitalium is of considerable clinical and public
health importance to the field.
Methods
This study was undertaken at the Melbourne Sexual Health
Centre (MSHC) between March 2005 and November 2007.
During that period, routine testing for M.genitalium was undertaken
for urethritis, epididymitis, cervicitis, pelvic inflammatory disease
(PID) and for sexual contacts of M.genitalium-infected men and
women. First pass urine samples or urethral swabs were
recommended for testing for M.genitalium in males, and cervical
swabs were recommended for testing in females, unless clinician or
patient preference necessitated high vaginal or first pass urine
samples to be obtained from females. Standardized epidemiolog-
ical and clinical data were collected electronically at the time
testing for M.genitalium was undertaken.
M.genitalium-infected men and women were treated with
azithromycin 1 g. All patients were asked to notify sexual partner(s)
to obtain testing and treatment. A routine test-of-cure (toc) was
recommended one month following azithromycin. Clinic nurses
contacted patients fortnightly on up to three occasions if they had
not attended for the toc. In those testing positive 3 weeks or more
following treatment, and where reinfection was considered unlikely,
moxifloxacin 400 mg daily for 10 days was administered, with
another toc one month after treatment with moxifloxacin.
Male contacts of men with M.genitalium were screened for
M.genitalium using throat, rectal and first-void urine samples.
Female contacts were tested using cervical, vaginal or first-void
urine samples. Contacts received presumptive treatment with
azithromycin 1 g, unless their partner had failed azithromycin
therapy in the absence of reinfection. In such cases, moxifloxacin
was administered. Testing for M.genitalium was by polymerase
chain reaction (PCR) according to the method described by
Yoshida et al. [16].
Data on the number of patients tested for M.genitalium, the
proportions testing positive, and demographic and behavioural
characteristics were analysed. Case files were reviewed in
individuals who tested positive for M.genitalium to establish the
treatment(s) prescribed to the index and sexual contacts, and the
clinical outcomes following treatment. Data were obtained to
determine the clinical characteristics of individuals in whom
M.genitalium persisted, the likelihood of reinfection from untreated
partners, and the response to treatment with moxifloxacin in those
failing to respond to azithromycin. Treatment outcomes following
azithromycin were recorded as eradication of M.genitalium if it was
not detected at toc1, or persistent infection with or without risk of
reinfection from sexual partners. All individuals in this study had
attended for medical care at MSHC. In line with the policy of our
institutional ethics committee and guidelines of the National
Health and Medical Research Council of Australia, consent and
ethics approval were not required, as this was an analysis of
routinely collected clinical data. Data were analysed using SPSS
(Version 15, Chicago, USA). Ninety-five percent confidence
intervals (CIs) were calculated for proportions. Differences
between categorical variables were compared using the Chi-
square or Fisher’s Exact test where appropriate. Patients were
excluded from the analysis where information or specimens were
not available.
Results
During the study period, 1538 men and 313 women were tested
for M.genitalium: 191 (10%) tested positive for M.genitalium (161
males [11%] and 30 females [10%]), 1660 (89%) patients tested
negative, and 5 (0.2%) had specimens that were repeatedly
unassessable. There were no significant differences in demograph-
ic, behavioural or clinical characteristics between infected and
uninfected men and women other than infected individuals were
more likely than uninfected to identify as a contact of M.genitalium
(data not shown), p,0.01.
Clinical and laboratory characteristics of M.genitalium-
infected patients
Table 1 shows the clinical characteristics of M.genitalium-infected
men and women, the specimens used to detect M.genitalium, and
the presence of genital coinfections. The median duration of
symptoms prior to presentation for males and females was 7 days
(range 1–120) and 10 days (range 1–360) respectively. Urethral
smears for Gram stain were obtained on 139 (86%) men with
urethral M.genitalium; 89 (64%) had $5 polymorphonuclear cells
(PMNs) per high power field on urethral smear. Vaginal and
cervical PMN counts were only available on 19 (60%) and 16
(57%) women respectively; of these, 10 (52%) had $5 PMN per
high power field on vaginal smear and 10 (63%) had $5 PMN per
high power field on cervical smear.
Treatment outcomes following azithromycin
A toc was available for 131 (69%) M.genitalium-infected
individuals after treatment (110 males and 21 females). The
median time to returning for the first toc (toc1) was 36 days (range
12–373); 119 (91%) patients returned within 12 weeks of
treatment. One hundred and twenty (92%) of these patients had
been treated with azithromycin 1 g only prior to toc. Eleven
participants (8%), however, were also treated with moxifloxacin
for persistent urethral symptoms in the interval following
azithromycin but prior to toc1.
Of the 120 patients (102 males and 18 females) treated with
azithromycin 1 g who proceeded to toc1, 101 (84%, 95%CI: 77–
90%) did not have persistence of M.genitalium. In 19 (16%, 95% CI:
10–23%) patients treated with azithromycin, M.genitalium persisted
at toc1; 11 (9%, 95% CI: 5–15%) were considered by clinicians to
not be at risk of reinfection (no sex since treatment or sex with a
partner who had been concurrently treated with azithromycin
1 g), Table 2. Eight (7%, 95% CI: 3–12%) patients with a positive
toc1 were considered as possibly at risk of reinfection from an
untreated or doxycyline-treated partner. Reinfection risk was not
consistently documented by clinicians for patients with negative
toc1s, so while it would have been helpful to compare reinfection
risk in those cured and not cured of M.genitalium-infection with
azithromycin 1 g, these data were not available.
M.genitalium was not detected at toc1 in the additional 11 (8%,
95% CI: 5–14%) patients who received moxifloxacin post-
azithromycin but prior to toc1, Table 2. They had been given
moxifloxacin at prior to toc1 as they had either already received
azithromycin from a physician prior to their presentation but were
still symptomatic and tested positive for M.genitalium upon
attending MSHC (n=4), or had received azithromycin at
presentation to MSHC (n=7) but had persistent symptoms and
were given moxifloxacin prior to toc1. Of the individuals given
moxifloxacin pre-toc1 only one had had contact with an untreated
partner and may have been at risk of reinfection, the remainder
had been celibate or had only had sex with an azithromycin-
treated partner.
Persistent M. genitalium
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Patients with M.genitalium detected at toc1 were significantly more
likely to report persistence of symptoms (91%), compared to
patients in whom M.genitalium was not detected (17%), p,0.0001.
There was no difference in the proportion of males (23%)
compared to females (24%) with persistence of M.genitalium post-
azithromycin or requiring moxifloxacin prior to toc1 for persistent
symptoms. However, heterosexual males were more likely to
experience azithromycin failure or to require moxifloxacin for
persistent symptoms prior to toc1 (28%) compared to men who
have sex with men (MSM),11%, p=0.04. Sex with a partner from
overseas (predominantly Asia) was reported in 20% of patients
failing azithromycin or requiring moxifloxacin prior to toc1,
compared to only 9% of patients in whom azithromycin
eradicated infection, however, this was not statistically significant,
p=0.11. Heterosexual males (19%) were not more likely than
MSM (15%) to have had a partner from overseas.
Of the 19 individuals with M.genitalium detected at toc1, 10
provided a second toc (toc2), Figure 1. Six patients with
persistent M.genitalium-infection had no risk of reinfection from
an untreated sexual partner; 5 had sexual partners who been
treated concurrently with azithromycin on one or more
occasions, and one had remained celibate. Notably, in three
couples simultaneous administration of azithromycin to sexual
partners on two consecutive occasions failed to eradicate
M.genitalium, and it was only when both index and partner were
concurrently treated with moxifloxacin did a third toc show that
M.genitalium had been eradicated. Four patients with persistent
infection post-azithromycin may have been at risk of reinfection
from an untreated or doxycyline treated partner. Importantly,
moxifloxacin eradicated persistent infection following azithro-
m y c i ni na l lc a s e s .
Table 1. Clinical and Laboratory Characteristics of
Participants Infected with M.genitalium.
Male n=161
(%)
Female n=30
(%)
Specimens in which M.genitalium was detected
First pass urine 155 (96) 3 (10)
Urethral swab 2 (1) -
Rectal swab 4 (3) -
Cervical swab - 23 (77)
High vaginal swab - 4 (13)
Clinical characteristics
Urethral discharge
no 35 (22)
yes 126 (78)
Dysuria
no 71 (44) -
yes 90 (56) 5 (17)
Urethral Irritation/itch
no 116 (72)
yes 45 (28)
Meatal Inflammation
no 138 (86)
yes 23 (14)
Vaginal Discharge
no - 15 (50)
yes - 15 (50)
Dyspareunia
no - 25 (83)
yes - 5 (17)
Lower Abdominal Pain
no - 23 (77)
yes - 7 (23)
Abnormal vaginal bleeding
no - 25 (83)
yes - 5 (17)
Mucopurulent cervicitis
no - 23 (77)
yes - 7 (23)
Cervical contact bleeding
no - 25 (83)
yes - 5 (17)
Cervical or adnexal tenderness
no - 21 (70)
yes - 9 (30)
Genital coinfections with M.genitalium
Urethral
M.genitalium
(n=157)*
Cervicovaginal
M.genitalium
(n=30)
C.trachomatis (urethra/urine)
Not detected 141 (90) -
Detected 15 (10) -
C.trachomatis (rectal)#
Not detected 24 (92) -
Male n=161
(%)
Female n=30
(%)
Detected 2( 8 ) -
C.trachomatis (cervix/vagina)
Not detected - 29 (97)
Detected - 1 (3)
N.gonorrhoeae (urethra)
Not detected 141 (91) -
Detected 14 (9) -
N.gonorrhoeae (rectal)
Not detected 26 (93) -
Detected 2( 7 ) -
N.gonorrhoeae (throat)
Not detected 27 (93) -
Detected 2( 7 ) -
Bacterial vaginosis
Not detected - 15 (56)
Detected 12 (44)
*There were no rectal coinfections. #Note rectal and pharyngeal STI screening
indicated in MSM (n=48) only and not performed in all cases. Testing for
Chlamydia trachomatis was by strand-displacement-amplification (ProbeTec-
ETCT-Amplified DNA-Assay, Becton Dickinson, MD, USA). Culture for Neisseria
gonorrhoeae was performed using modified-Thayer-Martin medium. Vaginal
smears assessed for bacterial vaginosis according to the Nugent method.
doi:10.1371/journal.pone.0003618.t001
Table 1. Cont.
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This large series provides strong evidence that azithromycin fails
toclearM.genitaliuminaconsiderableproportionofinfectedmenand
women. In only 84% (95% CI: 77–90%) of infected cases treated
with azithromycin 1 g was M.genitalium eradicated, while infection
persisted in 16% of cases; 9% of whom had no risk of reinfection
from untreated partners. In an additional 11 (8%) cases use of
moxifloxacin preceding toc prevented assessment of azithromycin
efficacy;however,moxifloxacin had beenprescribed by cliniciansfor
reasons related to probable azithromycin-resistance in the index or
their partner. Importantly, moxifloxacin 400 mg daily for 10 days
was effective in eradicating persistent infection in all cases in this
series who failed to respond to azithromycin, providing further data
to support the efficacy of this agent in persistent infection. There was
no difference in persistence of M.genitalium following azithromycin
betweenmalesandfemales;however,heterosexualmales,weremore
likely than MSM to experience persistence of M.genitalium following
azithromycin therapy.
We previously reported an azithromycin-failure rate of 28%
(95% CI: 15–45%) in men with M.genitalium urethritis [15]. The
numbers in this study were small (n=32) and the confidence
intervals were wide, but reinfection risk was carefully assessed, and
no patients had been re-infected or prescribed moxifloxacin prior
to a toc being obtained. Antimicrobial susceptibility testing of
M.genitalium isolates showed increased mean inhibitory concentra-
tions (MICs) to azithromycin .16 mg/l and susceptibility to
moxifloxacin (MIC range 0.031–0.125 mg/l). Mutations in region
V of the 23S rRNA gene were identified and explained the
mechanism of resistance [15]. In this current study we report an
azithromycin-failure rate of 16% (95%CI: 10–23%), which may be
conservative as it excludes the additional 8% of cases who
clinicians felt were experiencing azithromycin-failure and who
were treated with moxifloxacin prior to obtaining a toc. While the
Table 2. Reinfection risk and response of M.genitalium to azithromycin at first test of cure (n=131).
Reinfection risk in patients at toc1
M.genitalium detected
after 1 g azithromycin
at toc1 (n=19)
M.genitalium not detected
after 1 g azithromycin
at toc1 (n=101)
M.genitalium not detected
at toc1 but given moxifloxacin
prior to toc1* (n=11)
No sex prior to toc1 4 N/A 9
Sex prior to toc1 but with a partner
concurrently treated with azithromycin
7 N/A 1
Possible sex with untreated or doxycycline
treated partner prior to toc1
8 N/A 1
Reinfection risk not able to be assessed 0 101 0
toc1=first test of cure, N/A=data not available (no consistent documentation by clinicians of risk of reinfection in those with negative tests of cure).
*reasons for moxifloxacin use prior to toc1 indicated in the text but all related to persistent symptoms following azithromycin and/or suspected azithromycin resistance.
doi:10.1371/journal.pone.0003618.t002
Figure 1. *=cases with no risk of reinfection from untreated sexual partner, d=days, C1=case 1, C2=case 2, (A1)=first occasion 1 g azithromycin
administered, (A2)=second occasion 1 g azithromycin administered, (M1)=first occasion 400 mg daily of moxifloxacin for 10 days administered,
(D1)=first occasion 100 mg bd doxycycline for 7 days administered, SP=sexual partner, no Rx=no treatment administered, toc1=first test of cure
for case, toc2=second test of cure for case, +=positive, 2=negative, NA= not available,
#sp not retreated with azithromycin after first occasion,
?=treatment advised but could not be verified.
doi:10.1371/journal.pone.0003618.g001
Persistent M. genitalium
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intervals overlap and are considerably narrower in the larger
series. Most importantly, current clinical expectations are that
therapeutic agents for STIs should not be less than 95% effective.
Our findings support those of published studies that indicate 1 g of
azithromycin at best eradicates M.genitalium in only 84–85% of
treated patients [12,13].
Detection of M.genitalium by PCR in the early days following
therapy may reflect detection of non-viable DNA, and the interval
at which to perform a toc for M.genitalium following therapy has not
been well established. Studies indicate that detection of non-viable
C.trachomatis DNA following treatment falls over 1–2 weeks [17];
however there are no data available for M.genitalium. A significantly
higher proportion of cases with persistent detection of M.genitalium
DNA experienced persistent symptoms (91%) compared to those
with negative tocs (17%), indicating, as was found in our previous
research, that a positive toc is likely to reflect clinical disease
persistence rather than detection of non-viable DNA [15].
Recent studies have shown that M.genitalium is capable of
producing chronic infections in humans [18], and have focused on
potential mechanisms of resistance. It appears that M.genitalium can
undergo extensive gene sequence variation within a persistently
infected individual [18,19,20,21]. While mutations have been
identified to explain the mechanism by which azithromycin
resistance occurs [15], ongoing research indicates that resistance
may develop in vivo after both single-dose and extended regimens
of azithromycin (personal communication, Jorgen Jensen), suggesting that
widespread use of 1 g of azithromycin may be contributing to the
development of azithromycin-resistant M.genitalium.
There were some clear limitations to this study. This was a series
of patients attending an STD clinic with specific indications for
testing for M.genitalium. In this population, 11% of men and 10% of
women selectively tested for M.genitalium were infected. These
findings are relevant to symptomatic patients, but may not be
generalisable to unselected, asymptomatic individuals. Only sixty-
nine percent of patients testing positive for M.genitalium re-attended
for toc1, compared .90% in our previous study; it is possible that
men who re-attended were more likely to be experiencing
persistent symptoms and infection compared to those lost to
follow-up. Risk of reinfection relies on patient report, and may be
unreliable. However, careful documentation of reinfection risk was
undertaken in those with persistent M.genitalium due to attempts to
limit inappropriate prescription of moxifloxacin.
The findings from this study highlight a number of important
aspects in the diagnosis and treatment of M.genitalium. Mounting
data suggest that while azithromycin 1 g is moderately effective,
and superior to doxycyline, it is associated with unacceptable rates
of disease persistence, and its widespread use could be selecting for
resistance. In vitro data indicates that M.genitalium is highly sensitive
to moxifloxacin[22], and it appears to be effective in individuals
experiencing azithromycin failure; however, it is costly and there is
a significant risk of the development of resistance if used
inappropriately. As azithromycin is an effective, well-tolerated,
single-dose therapy for NGU and cervicitis it is administered
presumptively in many clinical settings, exposing a significant
proportion of symptomatic patients with M.genitalium to azithro-
mycin. This widespread practice may be selecting for azithromy-
cin-resistance in M.genitalium. With studies now indicating a failure
rate of at least 16%, follow-up of M.genitalium-infected patients
prescribed azithromycin is not only becoming important, but
further research is clearly needed to determine optimal first and
second-line therapeutic agents for M.genitalium. This includes more
rigorous evaluation of extended-azithromycin therapy, and
moxifloxacin. The lack of access to a commercial assay for
M.genitalium clearly poses a huge barrier for most clinical services in
not only testing for this infection, but in assessing treatment
efficacy and in monitoring the development of antibiotic resistance
more broadly.
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